Systematic Review of Genetic-Related Risk Factor and Inhibitor Epidemiology in People with Severe Hemophilia a from Africa: A 2023 Update

References (44)

1. 1 Haemophilias A and B [DOI]
2. 2 Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males [DOI]
3. 3 Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A [DOI]
4. 4 Genetic risk factors for inhibitors to factors VIII and IX [DOI]
5. 5 Inhibitors of Factor VIII in Black Patients with Hemophilia [DOI]
6. 6 Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe Hemophilia A: A 2013 Update [DOI]
7. 7 Single-Tube Polymerase Chain Reaction for Rapid Diagnosis of the Inversion Hotspot of Mutation in Hemophilia A [DOI]
8. 8 Prevalence of Inhibitors in a Population of 3435 Hemophilia Patients in France [DOI]
9. 9 The molecular analysis of haemophilia A: a guideline from the UK haemophilia centre doctors’ organization haemophilia genetics laboratory network [DOI]
10. 10 Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A [DOI]
11. 11 Expanding Hemophilia Care in Developing Countries [DOI]
12. 12 Factor VIII gene variants and inhibitor risk in African American hemophilia A patients [DOI]
13. 13 Genetic risk factors for inhibitors in haemophilia A [DOI]
14. 14 F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort [DOI]
15. 15 Advances in knowledge of inhibitor formation in severe haemophilia A [DOI]
16. 16 Sustainable clinical laboratory capacity for health in Africa [DOI]
17. 17 Hemophilia care in Africa: Status and challenges [DOI]
18. 18 Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role? [DOI]
19. 19 Factor VIII inhibitors in haemophiliacs: a single‐centre experience over 34 years, 1964–97 [DOI]
20. 20 Frequency of intron 1 and 22 inversions of factor VIII gene in Mexican patients with severe hemophilia A [DOI]
21. 21 HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdataset [DOI]
22. 22 Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients [DOI]
23. 23 Haemophilia in Côte d’Ivoire (the Ivory Coast) in 2017: Extensive data collection as part of the World Federation of Hemophilia’s twinning programme [DOI]
24. 24 Identification of the Intron 22 and Intron 1 Inversions of the Factor VIII Gene in Iraqi Kurdish Patients With Hemophilia A [DOI]
25. 25 First report of molecular diagnosis of Tunisian hemophiliacs A: Identification of 8 novel causative mutations [DOI]
26. 26 Factor VIII haplotypes frequencies in Tunisian hemophiliacs A [DOI]
27. 27 Life-threatening bleeding in patients with hemophilia (PWH): a 10-year cohort study in Dakar, Senegal [DOI]
28. 28 Inhibitor epidemiology and genetic‐related risk factors in people with haemophilia from Côte d’Ivoire [DOI]
29. 29 Clinical outcome and incidence of inhibitor development in severe hemophilia patients receiving low-dose prophylaxis: a 3-year follow-up study in Senegal, West Africa [DOI]
30. 30 HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation [DOI]
31. 31 Systematic molecular analysis of hemophilia A patients from Colombia [DOI]
32. 32 Rapid identification of the intron 22 inversion in haemophilia A [DOI]
33. 33 Molecular diagnosis of haemophilia A in patients from Senegal [DOI]
34. 34 First Molecular Analysis of F8 Gene in Algeria [DOI]
35. 35 Factor 8 Gene Mutations and Risk of Inhibitor Development in Hemophilia A Algerian Patients [DOI]
36. 36 Genomic alterations in the F8 gene correlating with severe hemophilia A in Egyptian patients [DOI]
37. 37 Ethnicity-specific impact of HLA I/II genotypes on the risk of inhibitor development: data from Korean patients with severe hemophilia A [DOI]
38. 38 FVIII and FIX inhibitors in people living with hemophilia in C ameroon, A frica: a preliminary study [DOI]
39. 39 Complications musculaires de l’hémophilie [DOI]
40. 40 Prevalence of inhibitor formation in a cohort of haemophilic children exposed to several products of various purities [DOI]
41. 41 The prevalence of anti-factor VIII and anti-factor IX antibodies among patients with hemophilia in Rabat, Morocco: a single center experience [DOI]
42. 42 Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent. [DOI]
43. 43 Screening of Intron 1 Inversion of Factor VIII gene in 130 patients with severe Haemophilia A from Pakistani cohort [DOI]
44. 44 The profile of patients with haemophilia managed at a haemophilia treatment centre in Pretoria, Gauteng [DOI]

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

• Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
• Comparative Analysis of Responses to Covid 19 between Europe, Asia, America and Africa- A Literature Review of Four Nations — shares topic coverage
• Molecular Determinants of Artemisinin Resistance in k13 Gene of Plasmodium falciparum — shares topic coverage
• Potential Impact of Climate Change on Termite Distribution in Africa — shares topic coverage
• The Challenges Facing in Commercial Biotechnology: Its Position in Egypt and Some African Countries — shares topic coverage